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AbstrAct
The mucosal surfaces of the body are 
characterised by complex, specialised 
microbial communities, often referred to as 
the microbiome. However, only much more 
recently—with the development of technologies 
allowing exploration of the composition and 
functionality of these communities—has 
meaningful research in this area become feasible. 
Over the past few years, there has been rapid 
growth in interest in the gut microbiome in 
particular, and its potential contribution to 
gastrointestinal and liver disease. This interest 
has already extended beyond clinicians to 
pharmaceutical companies, medical regulators 
and other stakeholders, and is high profile 
among patients and the lay public in general. 
Such expansion of knowledge holds the 
intriguing potential for translation into novel 
diagnostics and therapeutics; however, being 
such a nascent field, there remain many 
uncertainties, unanswered questions and areas 
of debate.
IntroductIon
There is a need for gastroenterologists and 
hepatologists to have an understanding of 
some of the key principles underlying the 
gut microbiome, given the implications it 
has for clinical medicine and the consider-
able interest that it increasingly holds for 
patients. The fast- moving nature of the 
field and sometimes complex terminology 
can create confusion. This review aims 
to give an overview of the central areas 
of knowledge about the gut microbiome, 
as well as highlighting the major future 
directions in this area.
overvIew of the gut mIcrobIome
what is the ‘microbiome’ and ‘microbiota’?
First coined by Joshua Lederberg in 2001, 
these terms are often used interchange-
ably. The human microbiota consists of up 
to 100 trillion microbial cells harboured 
by an individual, whereas the microbiome 
is the catalogue of these microbes and 
their genes living within a specific niche 
such as the human gut (table 1).1 The key 
technology used to study the composition 
of the gut microbiome is next- generation 
sequencing of bacterial genomes, using 
DNA extracted from samples (eg, stool, 
colonic mucosal biopsies) as starting 
material. This may be done using different 
techniques, each with their own associated 
strengths and weaknesses, but all relying 
on the principle of comparing the DNA 
sequences obtained from a biofluid with 
reference databases of microbial genomes 
(table 2). Bioinformatic tools then help 
to identify the specific bacterial taxo-
nomic composition within the sample.2 3 
However, while these sequencing technol-
ogies are very helpful for identifying ‘what 
is there’ in a sample, this does not give the 
full perspective as to what these bacteria 
are doing functionally, and how they are 
interacting with their mammalian host. As 
such, study of microbiome composition is 
now often supplemented by other systems 
biology techniques that give insight into 
microbiome function, such as metabo-
nomics and proteomics (figure 1); these 
are also reviewed elsewhere.2 3
Acquisition of the gut microbiome 
remains controversial, with the most 
robust evidence suggesting that it is a 
dynamic process that starts immediately 
after birth.4 The first (and most critical) 
contribution to the establishment of a 
microbiome is the vertical transmission of 
maternal microbiome at the time of birth. 
The specific patterns of colonisation of the 
gut microbiome within the first few weeks 
of life are thought to have crucial effects 
on its future composition.5 6 Following 
this, the infant gut microbiome undergoes 
rapid development over the first year of 
life, and appears to be established in an 
adult form by 3 years of age. Multiple 
factors play a key role in determining the 
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Table 1 Glossary of common terms related to the gut microbiome
Term Further details
Gut microbiota The total assemblage of microorganisms present within the gut mucosal environment.1
Gut microbiome The entire gut ecological habitat, including the microorganisms themselves, as well as their genomes, and the surrounding 
environmental conditions.1
Dysbiosis A term still used commonly to describe perturbation of the composition of the gut microbiome compared with what might be 
expected in the healthy host. However, in reality, often a poorly descriptive term without a specific biological definition.
Pathobiont Microorganisms that usually interact with the host symbiotically, but have the potential to act as pathogens and cause 
disease under certain conditions.
Faecal microbiota 
transplant (FMT)
Typically, a liquidised suspension of microbes (and their associated environmental milieu) derived from manipulated whole 
stool, administered to the gut of affected patients. Stool is obtained from healthy screened donors, and prepared using 
homogenisation, mixing with a diluent (eg, normal saline) and filtration. However, lyophilised FMT preparations are now also 
increasingly being used.
Table 2 Overview of common modalities of microbiome sequencing
Name of technique Overview Strengths Drawbacks
Metataxonomics (16S 
rRNA gene sequencing)
 ► The 16S rRNA gene is present in all 
prokaryotes, and consists of highly 
conserved regions interspersed by nine 
‘hypervariable’ regions. Hypervariable 
regions are of variable sequence and 
length between different bacteria.
 ► As such, PCR amplification and DNA 
sequencing of different bacterial 16S 
rRNA genes within a biofluid can allow 
identification of the different bacteria 
within samples.
 ► This is now a well- established, 
high- throughput technique, 
which is relatively cheap 
compared with alternatives.
 ► This technique may give detail down to bacterial 
genus level, but rarely gives any greater resolution 
than this.
 ► There are a number of factors that can bias the 
results obtained, for example:
 – There is variable use of primers, PCR conditions 
and analytic approach between different centres.
 – Different bacteria have different copy numbers 
of the 16S rRNA gene, influencing the apparent 
relative abundance of certain bacteria within a 
sample.
Shotgun metagenomics  ► This technique involves fragmentation 
and random sequencing of DNA from 
the collection of genomes and genes 
within the sample, and the use of 
advanced bioinformatic techniques to 
analyse the sequencing data obtained.
 ► Shotgun sequencing regularly 
gives characterisation down to 
species (and even possibly strain) 
level resolution.
 ► Since this technique sequences 
bacterial genes, it also gives 
insight into the microbial 
functionality of a sample.
 ► Gaps in knowledge in the accuracy and 
completeness of reference microbial genomic 
databases means large portions of sequencing data 
may be difficult to interpret.
 ► Datasets are large and complex, and experiments 
are much more expensive than metataxonomics.
 ► As per metataxonomics, there are still outstanding 
issues related to factors which may bias results.
gut microbial composition during its development, 
starting from mode of delivery (vaginal vs caesarean), 
to early feeding (breast vs formula), use of antibiotics 
in early life, diet and the environment.7–9
Of all the environmental influences on the gut micro-
biome, the contribution of diet is among the most 
important. It is well- established that diet can rapidly 
and reproducibly alter the gut microbiome, making 
human studies which do not control for diet difficult 
to interpret, and also implicating diet as a therapeutic 
target for altering the gut microbiome.10
what is the significance of a gut microbiome?
The gut microbiome is not a bystander, and has 
co- evolved with the host over thousands of years to 
form a complex and mutually beneficial relationship. 
Through this relationship, the microbiome provides a 
multitude of benefits to the host, including shaping the 
intestinal and systemic immune system,11 maintaining 
the healthy intestinal epithelium, harvesting energy 
from food12 and protection against pathogens.13 The 
alteration of the composition of the microbiome that 
results in disruption of these important physiological 
functions has sometimes been referred to as ‘dysbiosis’.
what is ‘dysbiosis’?
Dysbiosis is used to describe a change in diversity 
of microbiome, loss of specific beneficial microbes 
(symbionts) and expansion of potentially harmful ones 
(pathobionts). It is, however, a very non- descriptive 
and perhaps unhelpful term that often gets used to 
describe any shift in the gut microbial composition 
away from that seen in a ‘healthy host’ despite there 
being no agreed definition of what a ‘healthy gut micro-
biome’ is.14 The gut microbiome is largely composed 
of two groups at the phyla level, being dominated by 
the obligate anaerobic Bacteroidetes and Firmicutes, 
which make up 90% and are generally associated with 
health (beneficial). Other phyla present at lower levels 
are Actinobacteria, Fusobacteria, Verrucomicrobia 
and Proteobacteria, facultative anaerobes. The latter 
phylum comprises the common Gram- negative patho-
bionts such as Salmonella spp, Shigella and Escherichia 
coli. Despite uncertainty regarding the normal micro-
biome, remarkably congruent signals of ‘dysbiosis’ 
have been described (at least at a high taxonomic level) 
for nearly all chronic gastrointestinal (GI) and liver 
diseases including inflammatory bowel disease (IBD), 
Mullish BH, et al. Frontline Gastroenterology 2021;12:118–127. doi:10.1136/flgastro-2019-101376120
Education
Figure 1 Conventional and novel techniques for studying the gut microbiome. Traditional culture methods have drawbacks when applied 
to characterising the gut microbiome, as many species present are strictly anaerobic and not easily amenable to culture. The development of 
culture- independent DNA sequencing techniques has given insight into the composition of microbial communities; these are increasingly coupled 
with other techniques which elucidate microbiome functionality, such as metabonomics. This figure summarises the major culture- independent 
techniques in current use.
irritable bowel syndrome (IBS), primary sclerosing 
cholangitis and non- alcoholic fatty liver disease.15 It 
should however be emphasised that in most cases, 
dysbiosis merely shows an association rather than a 
cause. Furthermore, there is also increasing evidence 
to support a significant but less well- characterised 
contribution from the microbial communities of 
viruses and fungi (often referred to as the ‘virome’ and 
‘mycobiome’, respectively).16 17
the contrIbutIon of the gut mIcrobIome 
to dIseAse: specIfIc exAmples
Introduction
There are an ever- growing number of observational 
studies that have identified distinctive differences in 
the gut microbiome between patients with particular 
conditions and matched controls. Such changes are 
complex and nuanced, and are typically influenced 
by severity and distribution of disease, underlying 
treatment at the time of sampling, and region of the 
world in which the study is being performed, among 
other factors. However, in this section, a general 
summary is given of the key microbiome changes that 
accompany major GI and liver conditions.
Clostridioides difficile infection
Clostridioides difficile is a Gram- positive sporulating 
obligate anaerobe belonging to the Firmicutes phylum. 
This can sometimes apparently be a normal compo-
nent of the healthy gut microbiome, but in the context 
of treatment with broad- spectrum antibiotics, the 
colonic microbiome is damaged, with an almost total 
loss of Bacteroidetes, reduction in Firmicutes and an 
overgrowth of Proteobacteria; these changes allow C. 
difficile spores to germinate and for growth (and subse-
quent toxin production and infection) to occur .18 The 
contribution of faecal microbiota transplant (FMT) 
to restoration of the gut microbiome and treatment 
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of C. difficile is discussed in ‘The gut microbiome as 
therapy’ section.
Inflammatory bowel disease
Congruent signals with regard to microbiome disrup-
tion are seen in ulcerative colitis (UC) and Crohn’s 
disease (CD). It is well- recognised that there is a loss 
of bacteria belonging to the Firmicutes phylum19 and 
most studies (although not all) show the same with 
respect to Bacteroidetes.19–21 Faecalibacterium praus-
nitzii has often been highlighted as a bacterial species 
which can ferment non- absorbed dietary components 
into compounds beneficial to the host called short 
chain fatty acids; F. prausnitzii is reduced in preva-
lence in both CD and UC.22 Data have suggested that 
alteration in the gut microbiome plays a central role 
in driving UC; datasets highlighting the importance of 
Roseburia hominis,23 F. prausnitzii24 and Akkermansia 
muciniphila24 in the inflammation in UC have been 
published. An over- representation of Gram- negative 
pathobionts has been described in the gut microbiome 
of people with IBD,19 with species of note being E. 
coli25 and Fusobacterium spp.26
There are a lack of inception data in IBD, which 
leaves the question of which is the ‘chicken’ and which 
the ‘egg’ with respect to dysbiosis and inflammation/
treatment effects in the context of IBD. This was 
partially addressed by Gevers et al,27 who examined 
a large cohort of treatment- naïve children with new- 
onset CD. They were able to show a clear difference 
in the gut microbiome in this cohort compared with 
healthy controls, and therefore make a link between 
disease severity and dysbiosis. Recent efforts towards 
unravelling causal relationships were explored in a 
study that demonstrated induction of colitis in germ- 
free mice following transplantation of stool from 
patients with IBD.28
Regarding the ‘IBD microbiome’, much remains 
to be discovered regarding the contribution of non- 
bacterial components of the microbiome (such as 
phages and fungi), the effect of host genetics on the 
microbiome and mechanisms underlying the observed 
observations.
Ileal pouch anastomosis
Up to 40% of patients who undergo ileal pouch anasto-
mosis (IPAA) following subtotal colectomy for UC will 
experience pouchitis within 5 years. It is now estab-
lished that the microbiome in the pouch is the trigger 
for this, and broad- spectrum antibiotics are very effec-
tive for acute pouchitis.29 However, 10%–15% will go 
on to have chronic pouchitis, which may or may not 
respond to current therapy.30
The bacterial community present in the ileal mucosa 
starts to resemble that of the colon immediately after 
ileostomy closure,31 and this microbial dysbiosis 
is associated with the development of pouchitis.32 
Comparing non- inflamed with inflamed pouches, the 
latter show reduced microbiome diversity, similar but 
somewhat more pronounced than that seen comparing 
the bacterial diversity seen in UC compared with 
normal colon. In particular, in pouchitis, Bacteroidetes 
are reduced, whereas members of the Proteobacteria 
family are relatively increased.33 More recently, it was 
demonstrated that certain bacterial genera (Blautia, 
Dorea, Moryella, Suterella and Bacteroides) are associ-
ated with a better outcome in relation to treatment in 
patients with pouchitis.34 Furthermore, again similar 
to the situation in UC, it seems that generally, a reduc-
tion in families of the Firmicutes phylum and an 
increase in Proteobacteria are associated with inflam-
mation. It appears that the microbiome dysbiosis seen 
in pouches is similar when comparing newly formed 
with more mature pouches.35 Recently, in a prospec-
tive study of 19 patients undergoing colectomy and 
IPAA, 43% developed pouchitis in a year. Interestingly, 
in these patients, the microbiome in the colon prior to 
colectomy was highly predictive of the development of 
pouchitis.34
liver disease
Perturbation of the gut microbiome has been demon-
strated in liver diseases including non- alcoholic 
steatohepatitis/non- alcoholic fatty liver disease, alco-
holic hepatitis, primary sclerosing cholangitis, cirrhosis 
and hepatocellular carcinoma. This is an active area of 
interventional research using FMT.36 A recent open- 
label pilot study of FMT to treat patients with hepatic 
encephalopathy has shown an interesting signal 
regarding potential improvement in cognition.37 An 
association between specific toxin- producing bacteria 
and alcoholic hepatitis has recently been described, 
and bacteriophages were shown as a targeted route 
to remove these bacteria and possibly reverse alcohol- 
related liver disease in a rodent model.38
Irritable bowel syndrome
Dysbiosis has been shown between patients with IBS 
and healthy controls, with a change in the Firmicutes- 
to- Bacteroides ratio and reduction in bacterial diver-
sity,39 although certain recent data did not confirm this 
finding.40 As such, further research is needed to under-
stand the significance of the contribution of the gut 
microbiome to IBS.
colon cancer
Association studies in human cohorts have strongly 
associated several bacterial species with colon cancer.41 
Bacteroides fragilis and E. coli have both been impli-
cated, but the predominant bacterial species linked 
with colon cancer has been Fusobacterium nucle-
atum.42 This has been associated with a worse pheno-
type43 and prognosis.44 F. prausnitzii has been found 
to be under- represented in patients with human colon 
cancer.45 Guo et al examined the use of bacterial species 
as biomarkers to differentiate patients with colon 
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cancer from controls with benign GI disease (polyps 
and IBD) and healthy controls.46 They looked at ratios 
of F. prausnitzii/F. nucleatum and F. nucleatum/Bifido-
bacterium. Interestingly, F. nucleatum/Bifidobacte-
rium was found to be highly discriminatory versus all 
controls, raising the possibility of a microbiome- based 
biomarker for colon cancer. Further larger studies are 
needed, including interventional studies in humans.
Immune checkpoint inhibitor complications
It is well- established from animal models that respon-
siveness to treatment with checkpoint inhibitors is 
dependent on baseline microbiome profile47 and the 
impact of human gut microbiome on the efficacy and 
side- effect profile of anticancer therapies has also been 
recognised.48 49 Three recent independent studies on 
humans with solid tumours undergoing checkpoint 
inhibition showed the remarkable treatment respon-
siveness of the patients depending on baseline micro-
biome, although a consistent signal was not seen; this 
perhaps reflects the differing methodologies employed 
in these studies, or may reflect a focus on microbiome 
composition rather than functionality.50–52 While it 
appears that the composition of the gut microbiome 
is important in laying the foundation for successful 
checkpoint inhibitor treatment, another aspect of 
this treatment in which the microbiome seems key is 
toxicity. Diarrhoea is the main side effect of this highly 
effective cancer treatment, affecting 40% patients. Of 
these, a significant proportion go on to develop severe 
colitis, presumably related to the unfettered action 
of pro- inflammatory T cells. There have been several 
intriguing case series where FMT has been shown to be 
of great benefit in the setting of refractory checkpoint 
inhibitor colitis,53 and this is the subject of ongoing 
randomised trials.
the gut mIcrobIome As therApy
dietary manipulation of the gut microbiome
Detailed discussion of this area is outside the remit of 
this review, although this is a growing area of interest. 
In particular, there is an expanding field of research 
demonstrating that the efficacy of established dietary 
interventions for GI disease—including the low 
fermentable oligo, di, mono- saccharides and polyols 
(FODMAP) diet54 and enteral nutrition for active 
CD55 may be partly mediated by alterations in the gut 
microbiome.
prebiotics
Prebiotics are dietary components that are ferment-
able, which have a health benefit to their host. The 
most common of these are non- absorbable dietary 
fibres. They have been specifically defined as ‘selec-
tively fermented ingredients that allow specific 
changes, both in the composition and/or activity of the 
GI microflora that confers benefits on host well- being 
and health’.56 57 Prebiotics are neither hydrolysed 
nor absorbed in the upper GI tract, but are selec-
tively fermented by intestinal bacteria, and are able 
to alter the colonic bacteria.56 58 Animal models have 
shown that prebiotics can enhance mucosal integrity, 
and furthermore have been shown to reduce pro- 
inflammatory cytokines and reduce colitis.59 Prebi-
otics have an overall excellent safety profile but can be 
associated with abdominal pain, flatulence and diar-
rhoea at high doses.60 Specific prebiotics—such as the 
short chain fatty acids, including butyrate, acetate and 
propionate—have demonstrated benefits for reducing 
inflammation in IBD.61
probiotics
Probiotics are live microorganisms that, when admin-
istered, are intended to have a beneficial effect on the 
intestinal microbiome, and therefore confer a health 
benefit effect. Animal models have suggested that probi-
otics help promote the intestinal barrier.62 The studies 
to date looking at probiotics in IBD have been quite 
mixed, with some studies highlighting that both main-
tenance of remission or induction of remission could 
be achieved with probiotics, with others showing little 
or no benefit in IBD.63 A systematic review in 2017 
suggested that VSL#3 may be effective in inducing 
remission in active UC. Probiotics may be as effective 
as 5‐ASAs in preventing relapse of quiescent UC, but 
currently, the efficacy of probiotics in CD remains 
uncertain.64 The British Society of Gastroenterology 
(BSG) guidelines conclude that probiotics may have 
modest benefits in UC but are not recommended in 
CD.64 Importantly for patients with pouchitis, VSL#3 
has been shown to be effective in preventing pouchitis 
and maintaining remission after antibiotic treatment.65 
Multistrain probiotics have shown to be effective for 
treatment of IBS,66 and have been recommended for 
use in a recent American Gastroenterological Associ-
ation monograph on IBS management; however, this 
same monograph recommended that prebiotics were 
not used for this indication.67
faecal microbiota transplant
Overview
Initial studies of FMT for recurrent C. difficile infec-
tion (CDI) were observational, but these have now 
extended to a number of randomised trials since 
2013. These studies have collectively demonstrated 
that a single FMT for recurrent CDI has an efficacy of 
>80% in causing remission from the condition almost 
regardless of many variables related to administration, 
including whether upper GI or lower GI administra-
tion is used.68 FMT may also have superior efficacy 
compared with either vancomycin or fidaxomicin in 
the treatment of CDI.69 Other developments over 
this time have been the development of ‘frozen’ FMT 
protocols (allowing FMT to be pre- prepared and 
stored in freezers until the time of need),70 and the 
emergence of FMT capsules.71
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Figure 2 Summary of key considerations related to administration of faecal microbiota transplant (FMT) for treatment of recurrent CDI. As 
adapted from the British Society of Gastroenterology and Healthcare Infection Society FMT guidelines.74 CDI, Clostridioides difficile infection; GI, 
gastrointestinal; IBD, inflammatory bowel disease; NG, nasogastric.
While regulation of FMT has been approached 
differently in various countries, FMT regulation in the 
UK is within the remit of the Medicines and Health-
care products Regulatory Agency (MHRA), who regu-
late it as a medicinal product. Within the UK, FMT 
for recurrent CDI has also been approved by the 
National Institute for Health and Care Excellence72 
and Public Health England73; best practice regarding 
all aspects of FMT preparation and administration—
as well as donor selection, care of the recipient and 
governance aspects of running FMT services—have 
recently been described in joint BSG/Healthcare Infec-
tion Society guidelines.74 European75 and US76 guide-
lines addressing the role of FMT in the treatment of 
recurrent CDI have also been published. Key best prac-
tice aspects of FMT administration are summarised in 
figure 2.
Donor selection is an area that has been particularly 
high profile of late, given the described transfer of an 
extended- spectrum beta- lactamase- producing E. coli 
from donor to two FMT recipients in the USA, with 
bacteraemia occurring in both patients, and one of 
the patients dying.77 The protozoan intestinal parasite 
Blastocystis has also been shown to be transmissible 
via FMT in humans.78 Given some of the complexities 
in running FMT services (including logistics related 
to maintaining a donor pool, costs in screening and 
preparing material, need for sufficient freezer capacity, 
etc), there is a growing interest in ‘stool banks’, whereby 
a ‘hub’ centre provides FMT to ‘spoke’ centres.79
However, there are still gaps in knowledge related 
to FMT for the treatment of recurrent CDI. While 
FMT appears relatively safe over the short term, it is 
unknown if there are any potential long- term sequelae 
related to gut microbiome manipulation; the develop-
ment of FMT registries in certain countries (including 
the USA and Germany) is an attempt to monitor for 
this. Furthermore, mechanisms of action of FMT 
remain poorly understood, although there has been 
progress made in this area of late.80
FMT in the non-CDI setting
There have been four randomised studies using FMT 
as treatment for UC; these have collectively demon-
strated that FMT appears to be a relatively safe and 
effective modality for induction of remission for 
this condition (OR=2.89, 95% CI=1.36 to 6.13, 
p=0.006).81 82 However, these studies are markedly 
heterogenous with regard to key variables (including 
number of treatments, and mechanics of preparation 
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Table 3 Summary of studies of FMT in non- CDI conditions
Study condition Summary of outcomes from clinical studies
Inflammatory bowel disease Four randomised studies have collectively demonstrated FMT to be relatively safe and effective in inducing remission in mild- 
to- moderate UC. However, the relatively small size of trials and heterogeneity in their design has limited interpretability and 
applicability, and FMT is not currently recommended for this indication.74
Primary sclerosing cholangitis87 In a pilot study, 3/10 patients receiving FMT experienced a ≥50% decrease in ALP levels. There was correlation between bacterial 
taxa in the stool microbiome post- FMT and ALP levels.
Obesity88 In patients with obesity (but no other features of metabolic syndrome), no weight loss or change in GLP-1 levels were seen after 
FMT. However, stool microbiome and bile acid profiles were altered.
Metabolic syndrome89–91 FMT was associated with a transient improvement in peripheral insulin resistance, but this was not sustained. Furthermore, FMT 
from patients with metabolic syndrome into recipients with metabolic syndrome themselves resolved in transient worsening of 
insulin resistance.
Autism92
Intestinal decolonisation of 
multidrug- resistant organisms93
There are a growing number of case reports and case series suggesting that FMT may decolonise multidrug- resistant bacteria from 
the gut; however, a randomised controlled trial showed no difference in decolonisation rates between patients receiving FMT and 
those receiving no intervention.
Hepatic encephalopathy37 Patients receiving FMT (while receiving lactulose and rifaximin) may have fewer hospital admissions with encephalopathy 
compared with those receiving medical therapy alone.
Irritable bowel syndrome84 85 Variable results in the randomised studies performed to date, with overall disappointing outcomes. However, this may reflect 
heterogeneity of study design.
ALP, alkaline phosphatase; CDI, Clostridioides difficile infection; FMT, faecal microbiota transplant; GLP-1, glucagon- like peptide-1; UC, ulcerative colitis.
and administration), limiting their interpretability and 
applicability. Within the UK, the multicentre STOP- 
Colitis trial is ongoing, which is methodologically 
investigating the optimal route of FMT administration 
to patients with UC, and further establishing the effi-
cacy of this treatment for the condition.83
Results of randomised trials for IBS have been 
somewhat contradictory but overall disappointing at 
present, but this may be reflective of aspects of trial 
design.84 Further recent data suggest that FMT may 
have potential as a treatment for IBS, but that appro-
priate donor selection may be much important than is 
the case for recurrent CDI.85 Small single- centre studies 
of FMT for the treatment of hepatic encephalopathy 
show promising results,37 and a UK study investigating 
the safety of administration of FMT to patients with 
cirrhosis (Prospective, randomised placebo controlled 
feasibility trial of faecal mIcrobiota Transplantation in 
cirrhosis (PROFIT)) has now finished recruitment.86
The range of other conditions in which FMT has 
been reported to be of potential benefit are very wide 
in scope, including primary sclerosing cholangitis, 
obesity/metabolic syndrome, autism and in the intes-
tinal decolonisation of multidrug- resistant bacteria80 
(table 3).
conclusIon
New technologies to explore the gut microbiome 
have resulted in major developments in knowledge 
over a short period of time. The association between 
a perturbed gut microbiome and a range of different 
GI and liver diseases is now well- recognised, but 
whether the microbiome changes are cause, conse-
quence of incidental remains largely unclear while 
further mechanistic studies are awaited. The success 
of FMT for the treatment of CDI has created 
enthusiasm about a new paradigm of ‘microbiome 
therapeutics’. However, it is also clear that there 
remains layers of complexity and uncertainty in the 
biology of the gut microbiome that were not initially 
recognised. These will require careful deconvolu-
tion over the coming years in order to enable the 
maximum potential translation of this knowledge 
base into clinical benefit.
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